These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19034335)

  • 21. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ; González EA
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic Kidney Disease-Mineral Bone Disorder in Korean Patients: a Report from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD).
    Kim CS; Bae EH; Ma SK; Han SH; Lee KB; Lee J; Oh KH; Chae DW; Kim SW;
    J Korean Med Sci; 2017 Feb; 32(2):240-248. PubMed ID: 28049234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of High vs. Conventional Ergocalciferol Dose for Increasing 25-Hydroxyvitamin D and Suppressing Parathyroid Hormone Levels in Stage III-IV CKD with Vitamin D Deficiency/Insufficiency: A Randomized Controlled Trial.
    Thimachai P; Supasyndh O; Chaiprasert A; Satirapoj B
    J Med Assoc Thai; 2015 Jul; 98(7):643-8. PubMed ID: 26267985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Vitamin D Metabolites with Parathyroid Hormone, Fibroblast Growth Factor-23, Calcium, and Phosphorus in Dogs with Various Stages of Chronic Kidney Disease.
    Parker VJ; Harjes LM; Dembek K; Young GS; Chew DJ; Toribio RE
    J Vet Intern Med; 2017 May; 31(3):791-798. PubMed ID: 28186657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study.
    Górriz JL; Molina P; Bover J; Barril G; Martín-de Francisco AL; Caravaca F; Hervás J; Piñera C; Escudero V; Molinero LM;
    Nefrologia; 2013 Jan; 33(1):46-60. PubMed ID: 23364626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcium, phosphate and parathyroid metabolism in kidney transplanted patients.
    Ambrus C; Molnar MZ; Czira ME; Rosivall L; Kiss I; Remport A; Szathmari M; Mucsi I
    Int Urol Nephrol; 2009 Dec; 41(4):1029-38. PubMed ID: 19701690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study of chronic kidney disease-mineral bone disorders in newly detected advanced renal failure patients: A Hospital-based cross-sectional study.
    Etta PK; Sharma RK; Gupta A
    Saudi J Kidney Dis Transpl; 2017; 28(4):874-885. PubMed ID: 28748891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study.
    Gallieni M; Cucciniello E; D'Amaro E; Fatuzzo P; Gaggiotti A; Maringhini S; Rotolo U; Brancaccio D;
    J Nephrol; 2002; 15(2):165-70. PubMed ID: 12018633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis.
    Montenegro J; Cornago I; Gallardo I; García-Ledesma P; Hernando A; Martinez I; Muñoz RI; Romero MA
    Nephrology (Carlton); 2012 Jan; 17(1):26-31. PubMed ID: 22022934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.
    Tangri N; Wagner M; Griffith JL; Miskulin DC; Hodsman A; Ansell D; Naimark DM
    Am J Kidney Dis; 2011 Mar; 57(3):415-21. PubMed ID: 21131115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
    Shigematsu T;
    Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-trending of parathyroid hormone and phosphate in patients receiving hemodialysis.
    Block G; Do TP; Collins AJ; Cooper KC; Bradbury BD
    Clin Nephrol; 2016 Mar; 85(3):142-51. PubMed ID: 26784912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD.
    Ureña-Torres P; Metzger M; Haymann JP; Karras A; Boffa JJ; Flamant M; Vrtovsnik F; Gauci C; Froissart M; Houillier P; Stengel B;
    Am J Kidney Dis; 2011 Oct; 58(4):544-53. PubMed ID: 21803465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal transplant and secondary hyperparathyroidism.
    Gøransson LG; Bergrem H
    Scand J Urol Nephrol; 2007; 41(6):553-7. PubMed ID: 18050015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients.
    Mehrotra R
    J Ren Nutr; 2006 Apr; 16(2):100-18. PubMed ID: 16567266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between Parathyroid Hormone, 25 (OH) Vitamin D, and Chronic Kidney Disease: A Population-Based Study.
    Wang WH; Chen LW; Lee CC; Sun CY; Shyu YC; Hsu HR; Chien RN; Wu IW
    Biomed Res Int; 2017; 2017():7435657. PubMed ID: 28367447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ; Slatopolsky E
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guideline-practice gap in the management of predialysis chronic kidney disease mineral bone disorder in Japan.
    Hamano T; Fujii N; Matsui I; Nakano C; Inoue K; Tomida K; Mikami S; Okada N; Tsubakihara Y; Rakugi H; Isaka Y
    Ther Apher Dial; 2011 Jun; 15 Suppl 1():2-8. PubMed ID: 21595844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.